Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Cash Flow: 2013-2025

Historic Net Cash Flow for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $28.6 million.

  • Amphastar Pharmaceuticals' Net Cash Flow rose 1017.85% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 130.59%. This contributed to the annual value of $7.5 million for FY2024, which is 165.13% up from last year.
  • Amphastar Pharmaceuticals' Net Cash Flow amounted to $28.6 million in Q3 2025, which was up 500.57% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Cash Flow peaked at $119.8 million during Q3 2023, and registered a low of -$126.3 million during Q4 2023.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Net Cash Flow value was $4.8 million (recorded in 2025), while the average stood at $5.5 million.
  • Over the last 5 years, Amphastar Pharmaceuticals' Net Cash Flow had its largest YoY gain of 1,459.14% in 2023, and its largest YoY loss of 10,738.45% in 2023.
  • Amphastar Pharmaceuticals' Net Cash Flow (Quarterly) stood at $19.8 million in 2021, then tumbled by 105.89% to -$1.2 million in 2022, then slumped by 10,738.45% to -$126.3 million in 2023, then soared by 67.93% to -$40.5 million in 2024, then spiked by 1,017.85% to $28.6 million in 2025.
  • Its Net Cash Flow stands at $28.6 million for Q3 2025, versus $4.8 million for Q2 2025 and $31.1 million for Q1 2025.